Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) – A case report and review of literature

Rama Rajagopal, Maria Priyanka T

Endothelial rejection has been described following both m-RNA and vector-based vaccines for COVID-19. There is one case report of a stromal rejection described following influenza vaccination. We report a case of stromal rejection following vector-based COVID-19 vaccination, which might be the first case reported so far.

Key words: COVID-19 vaccine, penetrating keratoplasty, stromal rejection

Corneal graft endothelial rejection following vaccination is rare and has been described most commonly following influenza vaccination besides tetanus toxoid, hepatitis B, yellow fever, and herpes zoster.[1-5] Recently, endothelial rejection has been reported in keratoplasties following both mRNA and vector-based vaccines for SARS-CoV-2 coronavirus.[6-11] There is only one case report of a stromal rejection following influenza vaccination at 3 weeks in a deep anterior lamellar keratoplasty.[12] We report a case of a stromal rejection that occurred at 6 weeks following the second dose of COVID-19 vector vaccine (ChAdOx1 nCoV-19 CoronaVirus Vaccine (Recombinant) COVISHIELD) following penetrating keratoplasty, which may be the first case reported in literature so far.

Case Report

A 79-year-old single eyed patient presented with diminution of vision of one-week duration in the left eye. He had taken his second shot of COVID-19 vector vaccine (COVISHIELD) 6 weeks ago prior to the onset of symptoms. The right eye was eviscerated in 2008 following endophthalmitis. In the left eye, the patient underwent Descemet’s stripping endothelial keratoplasty in 2012 for pseudophakic bullous keratopathy followed by penetrating keratoplasty in 2017 for a failed graft. He was treated for Hodgkin’s lymphoma in 2016 for a period of 6 months. Both systemic and ocular evaluation 4 months prior to presentation was unremarkable. At presentation, his best-corrected visual acuity (BCVA) was 20/120. The graft had a localized central stromal edema suggestive of a stromal rejection.

Figure 1: Localized stromal edema

Figure 2: Faint corneal haze 2 months review

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Rajagopal R, Priyanka TM. Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) – A case report and review of literature. Indian J Ophthalmol 2022;70:319-21.
Table 1: Literature review of corneal graft rejection following COVID-19 vaccination

| Author          | Type of COVID-19 vaccine                                      | Details of surgery | Type and time of rejection                           |
|-----------------|--------------------------------------------------------------|--------------------|------------------------------------------------------|
| Crnej A et al.  | BNT162b2 mRNA SARS-CoV-2 vaccine                             | DMEK               | Endothelial rejection 7 days after the first dose    |
| Phylactou M et al. | BNT162b2 mRNA SARS-CoV-2 vaccine                             | Case 1 - DMEK      | Endothelial rejection                                |
|                 |                                                              |                    | Case 1-7 days after the first dose                    |
|                 |                                                              |                    | Case 2 - bilateral rejection, 3 weeks after the second dose |
| Rallis et al.   | BNT162b2 mRNA SARS-CoV-2 vaccine                             | DSAEK followed by PK | Endothelial rejection 3 days after the first dose   |
| Wasser LM et al.| BNT162b2 mRNA SARS-CoV-2 vaccine                             | Case 1 - PK followed by re-PK | Endothelial rejection                                |
|                 |                                                              |                    | Endothelial rejection                                |
| Abousy M et al. | BNT162b2 mRNA SARS-CoV-2 vaccine                             | Bilateral DSEK     | Endothelial rejection 3 days after the first dose    |
| Ravichandran et al.| ChAdOx1 nCoV-19 Corona Virus Vaccine Recombinant COVISHIELD | PK                 | Endothelial rejection                                |
| Our case        | ChAdOx1 nCoV-19 Corona Virus Vaccine Recombinant COVISHIELD   | PK                 | Endothelial rejection                                |

DMEK: Descemet’s membrane endothelial keratoplasty, DSAEK: Descemet’s stripping automated endothelial keratoplasty, PK: Penetrating keratoplasty

Discussion

Corneal transplantation compared to other solid organ transplantation is well tolerated due to immune privilege of the cornea and the absence of major histocompatibility complex (MHC) class II antigen presenting cells. Review of literature shows rare reports of unilateral or bilateral cases of endothelial rejection as early as day 1-8 weeks following vaccination most commonly following influenza vaccine. Recently, endothelial rejection following both mRNA and vector-based COVID-19 vaccines has been reported from day 1–3 weeks following vaccination[6–11] [Table 1]. Ours is probably the first case of stromal rejection following COVID-19 vaccination. Like in all previous reports, we can only speculate that this is vaccine related as the patient was systemically stable and there were no ocular risk factors. Similar to ours, Phylactou M et al.[7] and Abousy M et al.[11] have also reported endothelial rejection following the second dose of COVID-19 vaccine. Every immunization elicits an antigenic response due to activation of Class 2 MHC complex in all corneal layers, which in turn activates the immune status.[7] Adenovirus-vectored vaccines are known to induce strong cellular immunity and ChAdOx1nCoV-19 vaccination has been shown to be associated with marked increases in SARS-CoV-2 spike-specific effector T-cell responses as early as day 7, peaking at day 14, and maintained up to day 56.[13] However, considering the rare reports of rejections in patients receiving influenza, COVID-19, or other similar vaccines, one can presume that there must be other factors titrating immune responses culminating at times in rejection. Sometimes, the cause and effect relationship is not obvious and hence this may be underreported.

Conclusion

Hiking steroids prior to and after vaccination both primary and booster in all patients who have undergone transplantation is recommended. Rallis et al.[9] have suggested that it is prudent to defer elective corneal transplant by 3–6 months after the second dose of COVID-19 vaccines. Patients should also be counselled about these risks and to report at the earliest in case of symptoms of graft rejection to hasten visual recovery.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Solomon A, Frucht-Pery J. Bilateral simultaneous corneal graft rejection after influenza vaccination. Am J Ophthalmol 1996;121:708-9.
2. Wertheim MS, Keel M, Cook SD, Tole DM. Corneal transplant rejection following influenza vaccination. Br J Ophthalmol 2006;90:925-6.
3. Steinemann T, Koffler B, Jennings C. Corneal allograft rejection following immunization. Am J Ophthalmol 1988;106:575–8.
4. Vignapiano R, Vicchio L, Favuzza E, Cennamo M, Mencucci R. Corneal graft rejection after yellow fever vaccine: A case report. Ocul Immunol Inflamm 2021;4-7. doi: 10.1080/09273948.2020.1870146.

5. Matoba A. Corneal allograft rejection associated with herpes zoster recombinant adjuvanted vaccine. Cornea 2021. doi: 10.1097/ICO.0000000000002787.

6. Crnej A, Khoueir Z, Cherfan G, Saad A. Acute corneal endothelial graft rejection following COVID-19 vaccination. J Fr Ophtalmol 2021;44:e445-7.

7. Phylactou M, Li JO, Larkin DFP. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. Br J Ophthalmol 2021;105:893-6.

8. Rallis KI, Ting DSJ, Said DG, Dua HS. Corneal graft rejection following COVID-19 vaccine. Eye (Lond) 2021. doi: 10.1038/s41433-021-01671-2.

9. Wasser LM, Roditi E, Zadok D, Berkowitz L, Weill Y. Keratoplasty rejection after the BNT162b2 messenger RNA vaccine. Cornea 2021;40:1070-2.

10. Ravichandran S, Natarajan R. Corneal graft rejection after COVID-19 vaccination. Indian J Ophthalmol 2021;69:1953-4.

11. Abousy M, Bohm K, Prescott C, Bonsack JM, Rowhani-Farid A, Eghrari AO. Bilateral EK rejection after COVID-19 vaccine. Eye Contact Lens 2021;47:625-8.

12. Hamilton A, Massera R, Maloof A. Stromal rejection in a deep anterior lamellar keratoplasty following influenza vaccination. Clin Exp Ophthalmol 2015;43:838-9.

13. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78.